What is it about?
Topiroxostat therapy could be a better treatment option for HD patients who develop high serum UA levels after febuxostat administration.
Featured Image
Read the Original
This page is a summary of: Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients, Biological and Pharmaceutical Bulletin, January 2017, Pharmaceutical Society of Japan,
DOI: 10.1248/bpb.b17-00284.
You can read the full text:
Contributors
The following have contributed to this page
